Provention Bio, Inc. Form SC 13G January 22, 2019 7
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SCHEDULE 13G (Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.) ¹
Provention Bio, Inc. (Name of Issuer)
Common Stock, \$0.0001 par value (Title of Class of Securities)
74374N102 (CUSIP Number)
December 31, 2018 (Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[] Rule 13d-1(b)
[] Rule 13d-1(c)
[X] Rule 13d-1(d)

¹ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

NAME OF **REPORTING PERSON** S.S. OR I.R.S. **IDENTIFICATION** 1. NO. OF ABOVE **PERSON** Johnson & Johnson EIN: 22-1024240 **CHECK** THE **APPROPRIATE** BOX IF A (a) [] 2. MENBER] OF Α **GROUP** SEC USE ONLY 3. CITIZENSHIP OR PLACE OF **ORGANIZATION** 4. New Jersey **SOLE VOTING POWER** 5. -0-**SHARED VOTING** NUMBER OF **POWER SHARES BENEFICIALLY** 2,400,000* OWNED BY 7. SOLE **EACH DISPOSITIVE REPORTING PERSON POWER**

WITH

-0-

SHARED DISPOSITIVE POWER

8.

2,400,000*

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH

9. REPORTING

PERSON

2,400,000*

CHECK BOX IF THE

AGGREGATE

AMOUNT

10. IN [] ROW

(9)

EXCLUDES CERTAIN SHARES

PERCENT OF

CLASS

REPRESENTED

BY AMOUNT IN

11. ROW (9)

6.4%**

TYPE OF REPORTING PERSON

12.

CO

^{*} As of December 31, 2018.

^{**} Based on 37,351,562 shares of Common Stock outstanding as of November 5, 2018, as reported in the Issuer's Report on Form 10-Q for the period ended September 30, 2018 filed with the Securities and Exchange Commission on November 8, 2018.

NAME OF

REPORTING PERSON S.S. OR I.R.S. **IDENTIFICATION** NO. OF ABOVE 1. **PERSON** Johnson & Johnson Innovation-JJDC, Inc. EIN: 22-2007137 **CHECK** THE **APPROPRIATE** BOX IF (a)[] 2. A (b) [] **MEMBER** OF A **GROUP** SEC USE ONLY 3. CITIZENSHIP OR PLACE OF **ORGANIZATION** 4. New Jersey **SOLE VOTING POWER** 5. -0-**SHARED VOTING** NUMBER OF **POWER SHARES** 6. **BENEFICIALLY** 2,400,000* OWNED BY **EACH** 7. SOLE **REPORTING DISPOSITIVE PERSON** WITH

POWER

-0-

SHARED DISPOSITIVE POWER

8.

2,400,000*

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH

9. REPORTING PERSON

2,400,000*

CHECK BOX IF THE AGGREGATE

AMOUNT IN [] ROW

> (9) EXCLUDES CERTAIN SHARES

PERCENT OF

CLASS

REPRESENTED BY AMOUNT IN

11. ROW (9)

6.4%**

TYPE OF REPORTING PERSON

12.

10.

CO

^{*} As of December 31, 2018.

^{**} Based on 37,351,562 shares of Common Stock outstanding as of November 5, 2018, as reported in the Issuer's Report on Form 10-Q for the period ended September 30, 2018 filed with the Securities and Exchange Commission on November 8, 2018.

SCHEDULE 13G

ITEM 1(a) NAME OF ISSUER:

Provention Bio, Inc.

ADDRESS OF ISSUER'S ITEM 1(b) PRINCIPAL EXECUTIVE OFFICES:

> P.O. Box 666, Oldwick, NJ 08858

NAME OF ITEM 2(a) PERSON FILING:

> This statement is being filed by Johnson & Johnson, a New Jersey corporation ("J&J"), and Johnson & Johnson Innovation-JJDC, Inc., a New Jersey corporation ("JJDC"). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by J&J and JJDC are directly beneficially owned by JJDC. J&J may be deemed to indirectly

beneficially own

the securities that are directly beneficially owned by JJDC.

ADDRESS OF ITEM 2(b) PRINCIPAL BUSINESS OFFICE:

> J&J: One Johnson & Johnson Plaza, New Brunswick, NJ 08933 JJDC: 410 George Street, New Brunswick, NJ 08901

ITEM 2(c) CITIZENSHIP:

J&J: New Jersey JJDC: New Jersey

TITLE OF ITEM 2(d) CLASS OF SECURITIES:

Common Stock, \$0.0001 par value

ITEM 2(e) CUSIP NUMBER:

74374N102

STATEMENTS

ITEM 3 FILED
PURSUANT TO
RULES 13D-1(B)
OR 13D-2(B) OR
(C):

Not applicable.

ITEM 4 OWNERSHIP:

The information set forth in the cover pages to

Edgar Filing: Provention Bio, Inc. - Form SC 13G

this Schedule 13G is incorporated herein by reference thereto.

ITEM 5

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

Not applicable.

CI	IC.	ΙÞ	No	743	74N	1102

ITEM 60WNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

Not applicable.

ITEM $7^{\rm IDENTIFICATION}$ AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY:

Not applicable.

ITEM 8IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

Not applicable.

ITEM 9NOTICE OF DISSOLUTION OF GROUP:

Not applicable.

ITEM 10

CERTIFICATION:

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: January 22, 2019

JOHNSON & JOHNSON

By: /s/ Thomas Spellman III Name: Thomas Spellman III

Title: Secretary

JOHNSON & JOHNSON INNOVATION-JJDC, INC.

By: /s/ Kevin Norman Name: Kevin Norman Title: Assistant Secretary